- Home
- CORT
as of 12-12-2025 3:42pm EST
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 7.6B | IPO Year: | N/A |
| Target Price: | $139.00 | AVG Volume (30 days): | 690.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.87 | EPS Growth: | -30.72 |
| 52 Week Low/High: | $49.00 - $117.33 | Next Earning Date: | 11-04-2025 |
| Revenue: | $741,172,000 | Revenue Growth: | 17.92% |
| Revenue Growth (this year): | 23.79% | Revenue Growth (next year): | 40.97% |
AI-Powered CORT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Corcept Therapeutics Incorporated (CORT)
Chief Development Officer
Avg Cost/Share
$80.46
Shares
20,000
Total Value
$1,601,526.06
Owned After
1,875
See Remarks
Avg Cost/Share
$79.53
Shares
5,000
Total Value
$397,631.50
Owned After
10,277
SEC Form 4
See Remarks
Avg Cost/Share
$79.52
Shares
20,000
Total Value
$1,590,490.00
Owned After
7,904
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$79.77
Shares
40,000
Total Value
$3,190,796.00
Owned After
2,701,370
SEC Form 4
Chief Development Officer
Avg Cost/Share
$80.90
Shares
4,500
Total Value
$364,070.25
Owned After
1,875
SEC Form 4
Chief Development Officer
Avg Cost/Share
$75.56
Shares
20,000
Total Value
$1,507,121.70
Owned After
1,875
Chief Executive Officer
Avg Cost/Share
$75.10
Shares
28,782
Total Value
$2,152,105.36
Owned After
2,701,370
See Remarks
Avg Cost/Share
$73.65
Shares
5,000
Total Value
$368,244.50
Owned After
10,277
SEC Form 4
See Remarks
Avg Cost/Share
$73.99
Shares
20,000
Total Value
$1,479,816.00
Owned After
7,904
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$74.08
Shares
11,218
Total Value
$831,013.73
Owned After
2,701,370
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Guyer William | CORT | Chief Development Officer | Dec 2, 2025 | Sell | $80.46 | 20,000 | $1,601,526.06 | 1,875 | |
| Lyon Joseph Douglas | CORT | See Remarks | Dec 1, 2025 | Sell | $79.53 | 5,000 | $397,631.50 | 10,277 | |
| Maduck Sean | CORT | See Remarks | Dec 1, 2025 | Sell | $79.52 | 20,000 | $1,590,490.00 | 7,904 | |
| BELANOFF JOSEPH K | CORT | Chief Executive Officer | Dec 1, 2025 | Sell | $79.77 | 40,000 | $3,190,796.00 | 2,701,370 | |
| Guyer William | CORT | Chief Development Officer | Nov 25, 2025 | Sell | $80.90 | 4,500 | $364,070.25 | 1,875 | |
| Guyer William | CORT | Chief Development Officer | Nov 5, 2025 | Sell | $75.56 | 20,000 | $1,507,121.70 | 1,875 | |
| BELANOFF JOSEPH K | CORT | Chief Executive Officer | Nov 5, 2025 | Sell | $75.10 | 28,782 | $2,152,105.36 | 2,701,370 | |
| Lyon Joseph Douglas | CORT | See Remarks | Nov 3, 2025 | Sell | $73.65 | 5,000 | $368,244.50 | 10,277 | |
| Maduck Sean | CORT | See Remarks | Nov 3, 2025 | Sell | $73.99 | 20,000 | $1,479,816.00 | 7,904 | |
| BELANOFF JOSEPH K | CORT | Chief Executive Officer | Nov 3, 2025 | Sell | $74.08 | 11,218 | $831,013.73 | 2,701,370 |
Compare CORT vs Leading Stocks
See how CORT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CORT Corcept Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.